Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
7.01
-0.04 (-0.57%)
Oct 10, 2025, 12:52 PM EDT - Market open
Cullinan Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts that cover Cullinan Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $26, which forecasts a 270.90% increase in the stock price over the next year. The lowest target is $19 and the highest is $33.
Price Target: $26 (+270.90%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Cullinan Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 4 | 5 | 6 | 6 |
| Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 7 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +242.37% | Sep 12, 2025 |
| BTIG | BTIG | Strong Buy Reiterates $32 | Strong Buy | Reiterates | $32 | +356.49% | Sep 10, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +242.37% | Aug 21, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $35 → $28 | Buy | Maintains | $35 → $28 | +299.43% | Aug 18, 2025 |
| Stifel | Stifel | Strong Buy Initiates $22 | Strong Buy | Initiates | $22 | +213.84% | Jun 11, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
26.50M
EPS This Year
-3.76
from -3.11
EPS Next Year
-3.70
from -3.76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 84.0M | |||
| Avg | n/a | 26.5M | |||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.48 | -2.99 | |||
| Avg | -3.76 | -3.70 | |||
| Low | -3.93 | -4.31 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.